డైరెక్టర్ల నివేదిక Mahamaya Lifesciences Ltd.

Mar 31, 2026

Your Director''s are pleased to share with you the 24th Directors'' Report of your Company along with the Audited Standalone and
Consolidated Financial Statements for the financial year ended March 31, 2026 ("Year under review").

FINANCIAL SUMMARY AND HIGHLIGHTS

Key highlights of financial performance of your Company for the Financial Year 2025-26 are given below:

Amount (Rs. In Lacs)

Particulars

Standalone

Consolidated

31.03.2026 31.03.2025 31.03.2026 31.03.2025

Revenue from Operations

32,887.30

26,414.86

32,887.30

26,414.86

Other Income

115.93

302.44

115.93

302.44

Total Income

33,003.23

26,717.31

33,003.23

26,717.31

Total Expenses

30,595.58

24,979.77

30,615.02

24,980.97

Profit before tax

2,407.21

1,726.41

2,387.77

1,725.20

Total tax expenses

735.13

444.35

735.44

444.04

Profit for the year

1,672.08

1282.07

1,652.33

1281.16

EPS

8.43

7.55

8.33

7.52

During the year under review, Standalone revenue is Rs.
32,887.30 lacs as compared to Rs. 26,414.86 lacs in the
prior year. Profit before Tax reported to Rs. 2,407.21 lacs
as compared to profit of Rs. 1,726.41 lacs in the prior year.
Consolidated EBITDA for the year under review increased
by 10.42% from Rs. 3,426.32, lacs in the prior year to Rs.
2596.61 lacs primarily due to increase in sales. The Company''s
Standalone Profit for the year ended 31st March 2026 is Rs.
1672.08 lacs as against Standalone Profit of Rs. 1,282.07 lacs
for the prior financial year.

Consolidated revenue has also increased to Rs. 32,887.30
lacs from Rs. 26,414.86 Lacs. Your Company has posted
Consolidated profit before Tax of Rs. 2,387.77 lacs in the
current financial year as against Consolidated profit before
Tax of Rs. 1,725.20 lacs in the prior financial year. The
Company''s Consolidated profit for the year ended 31st March
2026 is Rs. 1,652.33 lacs as against Consolidated Profit of Rs.
1281.16 lacs in the prior financial year.

CONSOLIDATED FINANCIAL STATEMENT

In accordance with the provisions of the Act, the audited
Consolidated Financial Statement forms part of the Annual
Report. The highlights of consolidated financial statements
are included in tables above.

TRANSFER TO RESERVE

The Board of Directors has approved the retention of the
entire profit i.e., Rs. 1,652.33 Lakhs for FY26 in the retained
earnings.

DIVIDEND

The Company doesn''t declare or paid any dividend for the
Financial Year 2025-26.

STATE OF COMPANY''S AFFAIRS

Mahamaya Lifesciences Limited is a dynamic agrochemical
and crop nutrition enterprise engaged in the research,
manufacturing, registration, and global distribution of high-
performance crop protection products, biostimulants,
and specialized plant nutrients. Operating an advanced
formulation facility in Dahej, Gujarat, with robust regulatory
and quality control capabilities, the Company serves both
domestic rural markets and international geographies
spanning the Middle East, Africa, and Latin America. Following
its successful public listing on the BSE SME platform, the
Company continues to drive sustainable growth by expanding
its high-margin biological and combination product portfolios,
deepening global B2B partnerships, and investing in process
automation and eco-friendly agricultural innovations.

During the year under review, the Company had filed its Red
Herring Prospectus (RHP) and Prospectus with the Bombay
Stock Exchange (BSE), SME Platform and got listed its equity
shares on BSE Limited w.e.f November 18, 2025.

TRANSFER OF UNCLAIMED DIVIDEND TO INVESTOR
EDUCATION AND PROTECTION FUND

During the financial year under review, the Company did not
declare or pay any dividend. Consequently, there was no

amount liable to be transferred to the Investor Education
and Protection Fund (IEPF) pursuant to Section 125 of the
Companies Act, 2013.

CHANGE IN THE NATURE OF BUSINESS, IF ANY:

During the financial year under review, there was no change
in the nature of business of the Company. Accordingly, the
disclosure under Rule 8(5)(ii) of the Companies (Accounts)
Rules, 2014 is not applicable.

DEPOSITS

The Company has not accepted any public deposits under
Sections 73 & 76 of the Companies Act, 2013 read with
Companies (Acceptance of Deposits) Rules, 2014 during the
year Financial Year 2025-26 under review.

Details relating to deposits covered under Chapter V of the
act -

a. Accepted during the year; - NIL

b. Remained unpaid or unclaimed as at the end of the year; -
NIL

c. Whether there has been any default in repayment of
deposits or payment of interest thereon during the year
and if so, number of such cases and the total amount
involved- None.

i. At the beginning of the year; - NA

ii. Maximum during the year; - NA

iii. At the end of the year; - NA

REGISTRAR & SHARE TRANSFER AGENTS

The Company had appointed M/s KFin Technologies Limited
as its Registrar & Share Transfer Agent.

Details of RTA

Name

KFin Technologies Limited

Address

Selenium, Tower B, Plot No- 31& 32, Financial District, Nanakramguda, Serilingampally, Hyderabad - 500032,
Telangana, India.

Contact No

022 46170911

Email Id

[email protected]

Website

www.kfintech.com

SUBSIDIARY AND ASSOCIATE COMPANIES

As on 31st March 2026, the Company has one subsidiary:

Name of Subsidiary Group Country of Incorporation Percentage Holding As at March 31, 2025

Mahamaya Lifesciences FZE

United Arab Emirates

100%

Total capital contribution to be made in Mahamaya
Lifesciences FZE, is AED 150,000/- out of which, the Company
has remitted AED 10,000 in 2018 & AED 15,000 in 2019 and is
planning to remit the balance in FY 26-27 and complete the
investment.

A statement containing the salient features of the financial
statement of our subsidiaries in the prescribed Form AOC-1 is
attached herewith as
“Annexure-F".

Further, the Company does not have Joint Venture or
Associate Company.

SHARE CAPITAL

Authorised Share Capital

As on March 31, 2026, the authorized share capital of the
Company stood at Rs. 25,00,00,000/- (Rupees Twenty-Five
Crores Only) divided into 2,50,00,000 (Two Crore Fifty Lacs
only) Equity Shares of Rs. 10/- (Rupee Ten only).

Paid up Share Capital

During the financial year under review, the Paid-up Share
Capital of the Company increased from Rs. 17,76,62,000/-
(Rupees Seventeen Crores Seventy-Six Lacs Sixty-two
Thousand only) to Rs. 23,40,50,000/- (Rupees Twenty-
three Crores forty lacs and fifty thousand only) divided into
2,34,05,000 (Two Crores Thirty Four Lakhs and Five Thousand
only) Equity Shares of Rs. 10/- through fresh issue of equity
shares in Initial public offer.

ALTERATION OF MEMORANDUM OF ASSOCIATION &
ARTICLES OF ASSOCIATION

During the year under review, your Company has not altered its
Memorandum of Association and Article of Association.

REGISTERED OFFICE OF COMPANY

During the year under review, there is no change in the
registered office of your company

CHANGE IN NATURE OF BUSINESS

There has been no change in the nature of business of the
Company.

LISTING OF SHARES

During the financial year under review, the Company
successfully completed its Initial Public Offer ("IPO") through
the Book Building Process and listed its Equity Shares on the
SME Platform of BSE Limited. The IPO comprised a Fresh Issue
of 56,38,800 Equity Shares aggregating to Rs.64.28 Crore and
an Offer for Sale of 5,40,000 Equity Shares by the Promoter
Selling Shareholders aggregating to Rs.6.16 Crore, taking the
total Issue Size to 61,78,800 Equity Shares aggregating to
Rs.70.44 Crore.

The Equity Shares were issued at an Issue Price of ''114 per
Equity Share (including a premium of Rs.104 per Equity Share).

The IPO opened for subscription on November 11, 2025, and
closed on November 13, 2025.

The Basis of Allotment was finalized on November 14, 2025,
the Equity Shares were allotted on the same date, and
the Company''s Equity Shares were listed and admitted to
trading on the SME Platform of BSE Limited with effect from
November 18, 2025. The Company''s Equity Shares are listed
under BSE Scrip Code: 544466, Symbol: MAHAMAYA, and
ISIN: INE0U9D01019. KFin Technologies Limited acted as the
Registrar to the Issue.

The proceeds from the Fresh Issue are being utilised for
the purposes stated in the Prospectus, including funding
of working capital requirements, capital expenditure,
repayment/prepayment of certain borrowings, and general
corporate purposes. The proceeds received from the Offer for
Sale were paid directly to the respective Selling Shareholders,
and the Company did not receive any part of such proceeds.
During the financial year under review, there was no deviation
or variation in the utilisation of the proceeds raised through
the Fresh Issue from the objects stated in the Prospectus, and
the utilisation of funds is in compliance with the applicable
provisions of the Companies Act, 2013 and the applicable
SEBI regulations. However, Board approval was sought for
extension of timeline for utilisation of Proceeds. The details
of extension sought is as follows:

The Company received the IPO Net Proceeds in November
2025, leaving a limited execution window during FY 2025-26.
Based on a technical evaluation and certificate dated March
3, 2026, issued by Independent Chartered Engineer Mr. Kruten
H. Patel, the capital expenditure projects aggregating to
''3,570.23 Lakhs are being implemented in a phased manner
to accommodate multi-stage engineering, civil works,
machinery lead times, and technical upgrades. Accordingly,
the Board of Directors approved the revised completion

timelines: the Warehouse facility (''252.54 Lakhs) on or before
March 31, 2026; the Expansion of Existing Manufacturing
Facilities (''375.34 Lakhs) during FY 2026-27; and the New
Technical Manufacturing Plant (''2,942.35 Lakhs) during FY
2027-28.

This timeline extension is covered under the Prospectus
disclosures and does not constitute a variation in the objects
under Section 27 of the Companies Act, 2013, or SEBI ICDR
Regulations.

There is no change in the scope, capacity, or allocated
amounts, and any incidental cost variations will be met
entirely through internal accruals.

Annual Listing Fees for FY 2026-27 have been paid to BSE
Limited.

MONITORING AGENCY AND UTILISATION OF IPO
PROCEEDS

Pursuant to Regulation 41 of the SEBI (Issue of Capital and
Disclosure Requirements) Regulations, 2018, Infomerics
Valuation and Rating Limited was appointed as the Monitoring
Agency to monitor the utilisation of the proceeds of the
Company''s Initial Public Offer (IPO).

The Monitoring Agency has submitted its reports for the
relevant period to BSE Limited. Based on the Monitoring
Agency Reports and the quarterly Statement of Deviation(s)/
Variation(s) placed before the Audit Committee and the Board
of Directors, the Company confirms that the IPO proceeds
have been utilised for the objects stated in the Prospectus and
that there has been no deviation or variation in the utilisation
of the IPO proceeds during the financial year under review.

The status of utilisation of the IPO proceeds as on March 31,
2026 is given below:

Particulars

Amount (Rs. in Crore)

Gross Proceeds from Fresh Issue

61.96

Amount Utilised

29.17

Balance Unutilised

32.79

The unutilised funds, if any, have been kept in accordance
with the provisions of the Prospectus and applicable SEBI
Regulations until their utilisation for the approved objects of
the Issue.

CONSOLIDATED FINANCIAL STATEMENTS

In accordance with the provisions of the Companies Act,
2013 and the relevant Accounting Standards (specifically
Accounting Standard 21 (AS 21) on "Consolidated Financial
Statements") issued by the Institute of Chartered Accountants
of India (ICAI) / notified by the Ministry of Corporate Affairs,
the Audited Consolidated Financial Statements are attached
and form an integral part of this Annual Report.

BOARD OF DIRECTORS

The composition of the Board is in the compliance with the applicable provisions of the Companies Act, 2013 and the rules framed
thereunder and other applicable laws.

As on March 31, 2026, the Board of Directors of the Company comprised of 6 Directors, as detailed below:

S. No.

Name

DIN

Designation

1 Mr. Krishnamurthy Ganesan

00270539

Managing Director

2

Mrs. Lalitha Krishnamurthy

00425675

Whole-time Director

3

Mr. Prashant Krishnamurthy

02179512

Director

4

Dr. Charudatta Digambar Mayee

03607287

Independent Director

5

Mr. Sekhar Kavasseri Rajagopalan

03168413

Independent Director

6

Dr. Gopal Krishna Raju

00860886

Independent Director

CHANGES IN DIRECTORSHIPS DURING THE YEAR
UNDER REVIEW

During the year under review, there was no change in the
Directors of the Company.

DIRECTORS LIABLE TO RETIRE BY ROTATION

In accordance with the provisions of Section 152 of the
Companies Act, 2013 and Rules made thereunder and
pursuant to Articles of Association of the Company Mr.
Prashant Krishnamurthy (DIN: 02179512) Director of the
Company, is liable to retire by rotation at the ensuing AGM
and being eligible, offers himself for re-appointment. The
Board of Directors recommends his re-appointment for the
consideration of the members of the Company at the ensuing
AGM.

DIRECTORS AND KEY MANAGERIAL PERSONNEL
(KMP)

As on March 31, 2026, the Board of Directors comprised
a balanced composition of six Directors, including three
Independent Directors, one Managing Director, one Whole¬
time Director, and one Executive Director.

With a strategic focus on strengthening board governance,
long-term leadership continuity, and executive stewardship,
the Board of Directors, at its meeting held on August 25, 2026,
approved appointments, re-appointments, and leadership re¬
designations, subject to the approval of the members at the
ensuing Annual General Meeting:

• Appointment of Independent Director: Appointed Mr.
Bhagirath Choudhary (DIN: 03224386) as an Additional
Director designated as Non-Executive Independent
Director (not liable to retire by rotation) for a first term of
three consecutive years with effect from August 25, 2026.

• Re-appointment of Independent Directors: Approved the
re-appointment of Dr. Gopal Krishna Raju (DIN: 00860886)

and Dr. Charudatta Digambar Mayee (DIN: 03607287) as
Independent Directors (not liable to retire by rotation) for
a second term of three consecutive years with effect from
December 11, 2026.

• Leadership Transition & Executive Re-designations:

o Re-designated Mr. Krishnamurthy Ganesan (DIN:
00270539) from Managing Director to Chairman &
Executive Non-Independent Director (liable to retire
by rotation) effective November 01, 2026.

o Re-designated Mr. Prashant Krishnamurthy (DIN:
02179512) from Executive Director to Managing
Director (not liable to retire by rotation) effective
November 01, 2026.

Key Managerial Personnel :

• Approved the elevation of Mr. Amarendra Mohapatra as
Chief Financial Officer (CFO) and Key Managerial Personnel
(KMP) of the Company, as well as Senior Management
Personnel under SEBI (LODR) Regulations, with effect
from November 01, 2026, based on the recommendation of
the Audit Committee and Nomination and Remuneration
Committee.

• Approved the appointment of Mr. Kush Mishra as Company
Secretary & Compliance Officer, Key Managerial Personnel
(KMP) under the Companies Act, 2013, and Senior
Management Personnel under SEBI (LODR) Regulations,
with effect from August 25, 2026.

DETAILS OF SUBSIDIARY/JOINT VENTURES/
ASSOCIATE COMPANIES

As on March 31, 2026, the Company has one wholly owned
foreign subsidiary, namely Mahamaya Lifesciences (FZE),
incorporated in the United Arab Emirates (UAE). The subsidiary
primarily facilitates the Company''s international market
expansion, product registrations, and global distribution of
crop protection formulations.

During the financial year under review:

• No new subsidiaries, joint ventures, or associate
companies were incorporated, acquired, or ceased to
exist.

• The Company does not have any Joint Venture or
Associate Company within the meaning of Section 2(6) of
the Companies Act, 2013.

Pursuant to the provisions of Section 129(3) of the Companies
Act, 2013 read with Rule 5 of the Companies (Accounts) Rules,
2014, a separate statement containing the salient features of
the financial statement of the subsidiary in the prescribed
Form AOC-1 is annexed to the Consolidated Financial
Statements and forms an integral part of this Annual Report.

DECLARATION OF INDEPENDENT DIRECTORS

The Independent Directors have submitted their declaration
under Section 149 and 150 of the Act read with rules made
thereunder with respect to their Independence and the
confirmation of compliance with the code of conduct for
Independent Directors prescribed in Schedule IV of the
Companies Act, 2013 and rules made thereunder.

Further, they have confirmed that they have obtained
registration with Indian Institute of Corporate Affairs as an
Independent Director, and such registration continues to be
valid.

Based on the declarations and confirmations received
from the Independent Directors, the Board is of the opinion
that none of the Independent Directors of the Company are
disqualified from being appointed as Independent Directors
of the Company.

The Independent Directors have confirmed that they are not
aware of any circumstance or situation, which exists or may
be reasonably anticipated, that could impair or impact their
ability to discharge their duties with an objective independent
judgment and without any external influence.

Further, in terms of Rule 8(5) of the Companies (Accounts)
Rule, 2014, the Board is of the opinion that all Independent
Directors of the Company possess requisite integrity,
expertise, experience and proficiency.

MATERIAL CHANGES AND COMMITMENT IF ANY
AFFECTING THE FINANCIAL POSITION OF THE
COMPANY OCCURED BETWEEN THE END OF THE
FINANCIAL YEAR TO WHICH THIS FINANCIAL
STATEMENTS RELATE AND THE DATE OF THE REPORT

Except as mentioned above, no other material changes
took place affecting the financial position of the Company
occurred between the end of the financial year to which this
financial statement relate and the date of the report.

AUDITORS AND AUDITORS'' REPORT
Statutory Auditors

At the 23rd Annual General Meeting of the Company held on 25th
September 2025, pursuant to the provision of the Companies
Act, 2013 and rules made thereunder, M/s. N Naresh & Co.,
Chartered Accountants (Firm Registration No.: 0011293S)
were appointed as the Statutory Auditors of the Company who
shall hold office till the conclusion of the 28th Annual General
Meeting.

The Auditor''s report read with the relevant Notes to Accounts
are self-explanatory and therefore do not require any further
explanation.

During the year under review, the Statutory Auditor has not
reported any matter of fraud under Section 143 (12) of the
Act, therefore no disclosure is required under Section 134(3)
Companies Act.

Internal Auditors

Pursuant to the provisions of the Companies Act, 2013
the Company is required to appoint Internal Auditors for
conducting the internal audit of the affairs of the Company.

Accordingly, the Company had appointed Internal Auditors
i.e. M/s CHANDRAMOULI AND ASSOCIATES LLP, Chartered

Accountants for Financial Year 2025-26.

ADEQUACY OF INTERNAL FINANCIAL CONTROLS

Your Company has laid down set of standards, processes
and structure which enables to implement Internal Financial
controls across the organisation with reference to Financial
Statements and that such controls are adequate and operating
effectively. During the year under review, no material or serious
deviation has been observed for inefficiency or inadequacy of
such controls.

A statement indicating development and implementation
of a risk management policy for the Company including
identification therein of elements of risk, if any, which in
the opinion of the Board may threaten the existence of the
Company.

The Board affirms that the Company has developed and
implemented a comprehensive Risk Management Policy.
This policy outlines a structured and proactive approach to
identifying, assessing, mitigating, and monitoring various
risks that could potentially impact the Company''s operations,
financial performance, and long-term sustainability.

COMPLIANCE WITH CODE OF CONDUCT

The Board of Directors has laid down a Code of Conduct for
all Board members and senior management personnel which
is available on the website of the Company i.e. https://www.
mahamayalifesciences.com. The Company has received

confirmations from all the Board members and senior
management personnel regarding compliance of the Code
during the year under review. A declaration signed by the
Managing Director in this regard is attached as ''Annexure E''

CORPORATE POLICIES

We seek to promote and follow the highest level of ethical
standards in our business transactions. The SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015
mandated the formulation of certain policies for all listed
companies. All the policies are available on the website of the
Company at https://www.mahamayalifesciences.com.

The Policies are reviewed periodically by the Board and
updated on the basis of requirement in accordance with
revision in compliance guidelines.

THE KEY POLICIES ARE AS FOLLOWS:

I. Nomination and Remuneration Policy

In accordance with the provisions of section 134 (3)(e)
of the Companies Act, 2013 read with the provisions of
Section 178(3) and 178(4) and Regulation 19 of the SEBI
(Listing Obligations and Disclosure Requirements)
Regulations, 2015, your Company has adopted the policy
on appointment of Directors and Senior Management and
succession planning for orderly succession to the Board
and the Senior Management, which inter - alia includes the
criteria for determining qualifications, positive attributes
and independence of Directors.

II. Whistle Blower Policy - Vigil Mechanism

Adequate vigil mechanism for Directors and Employees to
report their genuine concerns about unethical behaviour,
actual or suspected fraud or violation of the Company''s
code of conduct is in place and the same have been
disclosed on the website of the Company https://www.
mahamayalifesciences.com. No complaints under the
whistle blower policy were received during the Financial
Year 2025-26.

III. Corporate Social Responsibility ("CSR") Policy

At Mahamaya Lifesciences Limited, the Company believes
in inclusive growth and sustainable development, and
remains committed to creating a positive impact on
society. The CSR initiatives of the Company are guided by
its CSR Policy and are in alignment with the provisions of
Section 135 of the Companies Act, 2013.

During the year under review, the Company has complied
with the applicable provisions relating to CSR under the
Companies Act, 2013. The Company continues to focus on
undertaking meaningful CSR activities in identified areas,
with an emphasis on contributing towards social and
economic development.

The CSR initiatives of the Company are aimed at creating
long-term value for the community and are implemented in
accordance with the approved CSR Policy. The Company is
also exploring additional avenues to further strengthen its
CSR efforts and expand its outreach in the coming years.

The Annual Report on CSR activities for the financial
year 2025-26, detailing the objectives, implementation,
and outcomes of our CSR initiatives, is annexed to
this report as Annexure ''C''. The CSR Policy is available
on our website and can be accessed at: https://www.
mahamayalifesciences.com.

ENVIRONMENT, HEALTH, AND SAFETY (EHS)
MEASURES

As a responsible manufacturer of crop protection and plant
nutrition formulations, Mahamaya Lifesciences Limited
places the highest priority on environmental stewardship,
workplace safety, and process integrity across its operations,
particularly at its manufacturing unit in Dahej, Gujarat. The
Company continuously strives to align its manufacturing
practices with applicable environmental and occupational
safety benchmarks through proactive risk management and
sustainable initiatives:

• Pollution Control & Waste Management: The formulation
facility operates in adherence to the prescribed consent
conditions of the State Pollution Control Board. The
Company utilizes modern effluent treatment processes
(ETP), zero-liquid-discharge (ZLD) practices where
applicable, and secure containment systems. All hazardous
wastes generated during formulation and packaging are
segregated, stored in designated containment zones, and
handed over to authorized TSDF/re-processing agencies
in strict compliance with Hazardous Waste Management
Rules.

• Air Emission Controls & Process Safety: The
manufacturing facility is equipped with dedicated
scrubbers, dust extraction systems, and multi-stage bag
filters to ensure process emissions and ambient air quality
remain well within permissible statutory limits. Regular
stack monitoring and workplace air quality assessments
are conducted through accredited environmental
laboratories.

• Workplace Safety & Hazard Control: The Company
enforces Standard Operating Procedures (SOPs) for the
safe handling, storage, and processing of agrochemical
intermediates and finished formulations. All operational
zones are provided with mandatory Personal Protective
Equipment (PPE), eye-wash stations, safety showers, and
automated fire detection and suppression systems.

• Training, Emergency Preparedness & Safety Audits:

Comprehensive safety training is imparted to permanent
and contractual personnel, covering emergency
evacuation drills, safe chemical handling, and first-
aid response. Periodic internal safety inspections,
hazchem risk assessments, and environmental audits are
conducted to identify and eliminate potential operational
hazards.

• Employee Health Monitoring: Routine pre-employment
and annual medical check-ups, including targeted
occupational health screenings, are organized for all
operational employees working in formulation and
packaging areas to safeguard long-term health and well¬
being.

• Eco-friendly Formulation Innovations: The Company
continues to direct its formulation development towards
safer, water-based, and biological/biostimulant solutions,
reducing dependence on volatile organic solvents and
minimizing the overall environmental footprint across the
product life cycle

Secretarial Auditors & their Report

The Company had appointed M/s HPN & Associates, Company
Secretaries, to conduct the Secretarial Audit for the Financial
Year 2025-26. The Secretarial Audit Report received from M/s
HPN & Associates for the Financial Year ended March 31, 2026
is annexed herewith as
Annexure - D to this Report.

The Secretarial Auditor''s report is self-explanatory and
therefore do not require further explanation. A Secretarial
Compliance Report for the financial year ended March 31,
2026 on compliance of all applicable SEBI Regulations and
circulars/ guidelines issued thereunder, was obtained from
M/s HPN & Associates, Company Secretaries, Secretarial
Auditors.

Maintenance of Cost Records

Your Company is required to maintain cost records as
specified under Section 148(1) of the Companies Act, 2013,
and accordingly, such accounts and records are made and
maintained in the prescribed manner.

As per provision of the Companies Act, on recommendation
of the Audit committee, your directors have appointed M/s.
Yogesh Gupta & Associates, Cost Accountants (having Firm''s
Registration No. 00373) to conduct the audit of the Cost
Accounts of the Company.

A Resolution seeking ratification of remuneration payable to
M/s. Yogesh Gupta & Associates, Cost Accountants, for the
Financial Year 2026-27 is included in the Notice convening the
Annual General Meeting.

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

The report on Management Discussion and Analysis
as required under Regulation 34 and Schedule V of the
SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015 ("Listing Regulations") is presented in a
separate section, forming an integral part of this Annual
Report. Certain statements in the report may be forward¬
looking. Many factors may affect the actual results, which
could be different from what the Directors envisage in terms
of future performance and outlook.

CORPORATE GOVERNANCE

Pursuant to Regulation 15(2)(b) of SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015, the Corporate
Governance provisions contained in Regulations 17 to 27 and
clauses (b) to (i) and (t) of Regulation 46(2) are not applicable to
the Company being listed on the SME Platform of BSE Limited.

Notwithstanding the regulatory exemption, the Company
firmly believes that robust corporate governance is
fundamental to sustainable value creation, stakeholder trust,
and operational integrity. Accordingly, the Company remains
dedicated to upholding the highest standards of transparency,
accountability, and ethical business conduct. The Board of
Directors proactively adheres to sound governance practices,
comprising an optimal mix of executive and independent
directors, actively functioning committees, comprehensive
internal financial controls, and timely, transparent disclosures
to safeguard and enhance the interests of all stakeholders.

As a voluntary best practice and commitment toward
transparent disclosures, a detailed report on Corporate
Governance is annexed herewith as
Annexure-B and forms an
integral part of this Board''s Report.

EXTRACT OF ANNUAL RETURN

Pursuant to Section 92(3) read with Section 134(3)(a) of the
Act, the draft Annual Return for the year ended March 31, 2026
is available on the Company''s website and can be accessed at
www.mahamayalifesciences.com.

Further, the Company shall upload the Certified Annual Return
on the website of the company after filing of same with
Registrar of Companies in due course.

During the financial year 2025-26, the Board of Directors of the Company met 15 times and were duly attended by the Directors.
The interval between any two meetings did not exceed 120 days as per the provisions of Companies Act, 2013.

(Q1) April - June (Q2) July - September (Q3) October - December (Q4) January - March

04-April -25

26-Jul-25

03-Oct-25

17-Feb-26

09-May-25

29-Aug-25

08-Oct-25

-

14-June-25

-

28-Oct-25

-

-

-

28-Oct-25

-

-

-

06-Nov-25

-

-

-

10-Nov-25

-

-

-

14-Nov-25

-

-

-

14-Nov-25

-

-

-

02-Dec-25

-

S. No Name of the Director Attendance

1

Mr. Krishnamurthy Ganesan

15/15

2

Mrs. Lalitha Krishnamurthy

15/15

3

Mr. Prashant Krishnamurthy

15/15

4

5

Dr. Charudatta Digambar Mayee

15/15

Mr. Sekhar Kavasseri Rajagopalan

14/15

6

Dr. Gopal Krishna Raju

15/15

COMMITTEES OF THE BOARD

During the period under review, your Company had the following committees:

Audit Committee

The Board of Directors of your Company has duly constituted Audit Committee in accordance with Section 177 of the Act. During
the year under review, all the recommendations made by the Audit Committee were accepted by your Board.

The constitution of the Audit Committee is as follows:

S. No

Name of the Member

Position in Committee

1

Dr. Gopal Krishna Raju

Director (Independent & Non-Executive)

Chairman & Member

2

Dr. Charudatta Digambar Mayee

Director (Independent & Non-Executive)

Member

3

Mr. Krishnamurthy Ganesan

Managing Director

Member

During the year under review, the company has compiled in conducting the meeting as per terms of reference of Audit committee.

The complete details regarding the number of meetings held, dates of the meetings, and member attendance are provided in the
Corporate Governance Report, which forms an integral part of this Annual Report.

Nomination and Remuneration Committee

The Board of Directors of your Company has duly constituted Nomination and Remuneration Committee (NRC) in accordance with
Section 178 of the Act.

During the year under review, all the recommendations made by the NRC were accepted by your Board.

The constitution of the NRC is as follows:

S. No

Name of the Member

Position in Committee

1

Dr. Charudatta Digambar Mayee

Director (Independent & Non-Executive)

Chairman & Member

2

Dr. Gopal Krishna Raju

Director (Independent & Non-Executive)

Member

3

Sekhar Kavasseri Rajagopalan

Director (Independent & Non-Executive

Member

During the year under review, the company has compiled in conducting the meeting as per terms of reference of Nomination and
Remuneration committee (NRC).

The complete details regarding the number of meetings held, dates of the meetings, and member attendance are provided in the
Corporate Governance Report, which forms an integral part of this Annual Report.

COMPANY''S POLICY RELATING TO DIRECTORS'' APPOINTMENT, PAYMENT OF REMUNERATION AND DISCHARGE OF
THEIR DUTIES

Your Company has Nomination and Remuneration policy in place relating to the appointment of Directors, payment of managerial
remuneration, Directors'' qualifications, positive attributes, independence of Directors and other related matters as provided
under Section 178(3) of the Act. The aforesaid policy is uploaded on the website of the Company at www.mahamayalifesciences.
com.

The Remuneration Policy of the Company reflects the remuneration philosophy and principles of the Company and considers the
pay and employment conditions with peers/competitive market to ensure that pay structures are appropriately aligned. Ensure
reasonableness and sufficiency of remuneration to attract, retain and motivate competent resources.

Ensure a balance between rewarding personnel of the Company in relation to short and long-term performance of the Company.
Corporate Social Responsibility Committee

The Board of Directors of your Company has duly constituted Corporate Social Responsibility (CSR) Committee in terms of the
Section 135 of the Act.

The constitution of CSR Committee is as follows:

S. No

Name of the Member

Position in Committee

1.

Mr. Krishnamurthy Ganesan

Managing Director

Chairman & Member

2.

Mr. Sekhar Kavasseri Rajagopalan

Director (Independent & Non-Executive)

Member

3

Mrs. Lalitha Krishnamurthy

Whole Time Director

Member

During the year under review, the company has compiled in conducting the meeting as per terms of reference of Corporate Social
Responsibility committee.

The complete details regarding the number of meetings held, dates of the meetings, and member attendance are provided in the
Corporate Governance Report, which forms an integral part of this Annual Report.

Stakeholders'' Relationship Committee

The Board of Directors of your Company has duly constituted Stakeholder''s Relationship Committee (SRC) in terms of the Section
178 of the Act.

The constitution of the SRC is as follows

S. No

Name of the Member

Position in Committee

1

Dr. Gopal Krishna Raju

Director (Independent & Non-Executive)

Chairman & Member

2

Prashant Krishnamurthy

Executive Director & CFO

Member

3

Lalitha Krishnamurthy

Whole Time Director

Member

The Board carried out an annual performance evaluation of its
own performance and that of its Committees and Individual
Directors as per the formal mechanism adopted by the Board.
The performance evaluation of all the Directors was carried
out by the Nomination and Remuneration Committee of the
Company. The performance evaluation of the Chairman, the
Non-Independent Directors and the Board as a whole was
carried out by the Independent Directors of the Company. The
performance evaluation was carried out through a structured
evaluation process covering various aspects of the Board
functioning such as composition of the Board & committees,
experience & competencies, performance of specific duties
& obligations, contribution at the meetings and otherwise,
independent judgment, governance issues etc.

Code for Prevention of Insider Trading

The Company has adopted a Code of Conduct ("Code") to
regulate, monitor and report trading in Company''s shares by
Company''s designated persons and their immediate relatives
as per the requirements under the Securities and Exchange
Board of India (Prohibition of Insider Trading) Regulations,
2015. The Code, inter alia, lays down the procedures to be
followed by designated persons while trading/dealing in
Company''s shares and sharing Unpublished Price Sensitive
Information ("UPSI"). The Code covers Company''s obligation
to maintain a digital database, mechanism for prevention
of insider trading and handling of UPSI, and the process
to familiarize with the sensitivity of UPSI. Further, it also
includes code for practices and procedures for fair disclosure
of UPSI which has been made available on the Company''s
website https://mahamayalifesciences.com.

VIGIL MECHANISM/WHISTLE BLOWER POLICY

The Company has adopted a Whistle Blower Policy and has
established the necessary vigil mechanism for Directors and
employees in confirmation with Section 177 of the Act, to
facilitate reporting of the genuine concerns about unethical
or improper activity, without fear of retaliation. The vigil
mechanism of the Company provides for adequate safeguards
against victimization of Directors and employees who avail
of the mechanism and also provides for direct access to the
Chairperson of the Audit Committee in exceptional cases.
No person has been denied access to the Chairperson of the
Audit Committee. The said policy is uploaded on the website
of the Company https://mahamayalifesciences.com.

During the year under review, the Company has not received
any complaint under the whistle blower policy.

INTERNAL FINANCIAL CONTROL AND ITS ADEQUACY

The Board has adopted the policies and procedures for
ensuring the orderly and efficient conduct of its business,

including adherence to the Company''s policies, systems,
protocols and plan implementation for safeguarding of its
assets, the prevention and detection of frauds and errors, the
accuracy and completeness of the accounting records, and
the timely preparation of reliable financial disclosures.

IMPLEMENTATION OF RISK MANAGEMENT POLICY OF
THE COMPANY

The Company has a structured Risk Management Framework
designed to identify, assess, and mitigate risks appropriately.
The Board oversees the implementation and monitoring of the
risk management plan for the Company. The Audit Committee
has oversight in the area of financial risks and controls. The
major risks identified by the businesses are systematically
addressed through mitigation actions on a continual basis.

RELATED PARTY TRANSACTIONS

All transactions with related parties are placed before the
Audit Committee for its prior approval. An omnibus approval
from Audit Committee is obtained for the related party
transactions which are repetitive in nature. Prior approvals are
also being obtained for related party transactions which are
long-term in nature and are being placed for noting by Audit
Committee in compliance of requirements of SEBI Listing
Regulations. All transactions with related parties entered into
during the year under review were at arm''s length basis and
in the ordinary course of business and in accordance with
the provisions of the Act and the rules made thereunder, the
SEBI Listing Regulations and the Company''s Policy on Related
Party Transactions.

Particulars of contracts, arrangements, or transactions
entered into by the Company during FY26 falling under
the scope of Section 188(1) of the Act are provided in the
prescribed
Form AOC-2, attached herewith as Annexure G to
this report.

The Policy on Related Party Transactions is available on
the Company''s website and can be assessed using the link:
https:// www.mahamayalifesciences.com.

PARTICULARS OF LOANS, GUARANTEE OR
INVESTMENTS MADE UNDER SECTION 186 OF THE
COMPANIES ACT, 2013

Particulars of guarantee and investments made are given in
Notes to the Standalone Financial Statements, respectively,
forming an integral part of the Integrated Annual Report.
During Financial Year 2025-26, the Company has not given any
loan pursuant to Section 186 of the Act.

INSOLVENCY AND BANKRUPTCY CODE, 2016/ ONE¬
TIME SETTLEMENT

During the year under review, the Company has nothing to
report in terms of Clause (xi) and (xii) of sub-rule 5 of Rule 8

of the Companies (Accounts) Rules, 2014. During the year
under review, the Company has neither made any application
nor any proceedings are pending under the Insolvency and
Bankruptcy Code, 2016. Similarly, the Company has not made
any one-time settlement with banks or financial institutions
during the period under review.

CONSERVATION OF ENERGY, TECHNOLOGY
ABSORPTION, FOREIGN EXCHANGE EARNINGS AND
OUTGO

Pursuant to Section 134(3)(m) of the Companies Act, 2013
read with rule 8(3) of The Companies (Accounts) Rules,
2014, relevant details of energy conservation, technology
absorption and foreign exchange earnings and outgo are
detailed below:

A. Conservation of Energy

• Steps taken or impact on conservation of energy:

The Company continues to prioritize energy efficiency
across its formulation facility at Dahej, Gujarat, by
integrating energy-efficient LED lighting systems,
installing variable frequency drives (VFDs) on high-
load motors and agitators, optimizing boiler and chiller
operational cycles, and implementing automated
temperature-control mechanisms to minimize
baseline power consumption.

• Steps taken by the Company for utilizing alternate
sources of energy:
The Company is evaluating the
installation of rooftop solar photovoltaic systems at
its manufacturing premises and actively explores
procurement options for green power/open-access
renewable energy to progressively reduce dependency
on conventional grid power.

• Capital investment on energy conservation
equipment:
Capital expenditure incurred during
the year was directed towards retrofitting process
equipment with energy-efficient alternatives, process
automation, and upgrading electrical distribution
systems to curb transmission and operational losses.

B. Technology Absorption, Adaptation, and Innovation

• Efforts made towards technology absorption:

The Company has focused on advancing in-house
R&D capabilities for developing eco-friendly crop
protection formulations, high-margin biostimulants,
and novel combination chemistries. Process
optimization studies were conducted to enhance
active ingredient stabilization, reduce batch cycle
times, and minimize process waste.

• Benefits derived: Enhanced product efficacy,
improved chemical recovery and yield, shortened

delivery turnaround times, and reduced environmental
footprint through low-solvent and water-based
formulations.

• Imported Technology: The Company has not imported
any standalone technology during the financial year
under review. All process improvements, recipe
standardizations, and formulation enhancements
are carried out through internal research, technical
collaborations, and indigenous engineering efforts.

• Expenditure incurred on Research and Development
(R&D):
The Company continuously incurs revenue and
capital expenditure on technical development, quality
assurance, analytical instrumentation, and registration
data generation to sustain product compliance across
domestic and overseas jurisdictions.

C. Foreign Exchange Earnings and Outgo : Detailed line-
item disclosures and breakdown of foreign currency
transactions are provided in Note No. 35, Note No. 36 and
Note No. 37 of the Notes forming part of the Standalone
Financial Statements.

PARTICULARS OF EMPLOYEES AND REMUNERATION

Pursuant to the amendment in the Section 197 of the
Companies Act, 2013 read with Rule 5(1) of the Companies
(Appointment and Remuneration of Managerial Personnel)
Rules, 2014, a detailed statement is attached as
Annexure-A.
Apart from that, there are no Employees in the Company whose
particulars are required to be disclosed in accordance with
Rule 5(2) of the Companies (Appointment and Remuneration of
Managerial Personnel) Amendment Rules, 2016 in the report.

DETAILS OF SIGNIFICANT AND MATERIAL ORDERS
PASSED BY THE REGULATORS/COURTS/TRIBUNALS
IMPACTING THE GOING CONCERN STATUS AND THE
COMPANY''S OPERATIONS IN FUTURE

There was no such significant and material order passed
by the regulators/courts/tribunals during the financial year
under review. However, your Company was converted from
Private Limited Company to Public Limited Company during
the financial year under review.

DISCLOSURE UNDER THE SEXUAL HARASSMENT OF
WOMEN AT WORKPLACE (PREVENTION, PROHIBITION
AND REDRESSAL) ACT, 2013

To foster a positive workplace environment, free from
harassment of any nature the Company has constituted an
Internal Complaints Committee (ICC) to consider and address
the sexual harassment complaints in accordance with the
Sexual Harassment of Women at Workplace (Prevention,
Prohibition & Redressal) Act, 2013 and has in place an Anti¬
Sexual Harassment Policy in line with requirements of the

said Act. The following is a summary of sexual harassment
complaints received and disposed-off during the financial
year 2025-26:

PARTICULARS

DETAILS

STATUS

No. of complaints filed during the
financial year

None

NA

No. of complaints pending as on
end of the financial year

None

NA

No. of cases pending for more
than ninety days

None

NA

MATERNITY BENEFIT PROVIDED BY THE COMPANY
UNDER MATERNITY BENEFIT ACT 1961

The Company declares that it has duly complied with the
provisions of the Maternity Benefit Act, 1961. All eligible
women employees have been extended the statutory benefits
prescribed under the Act, including paid maternity leave,
continuity of salary and service during the leave period, and
post-maternity support such as nursing breaks and flexible
return-to-work options, as applicable.

The Company remains committed to fostering an inclusive
and supportive work environment that upholds the rights
and welfare of its women employees in accordance with
applicable laws.

DIRECTORS'' RESPONSIBILITY STATEMENT

In accordance with the provisions of Section 134(5) of
the Companies Act, 2013 the Board hereby submits its
Responsibility Statement for the year under review, that

a) in the preparation of the annual accounts, the applicable
accounting standards had been followed along with proper
explanation relating to material departures;

b) the Directors had selected such accounting policies
and applied them consistently and made judgments and
estimates that are reasonable and prudent so as to give
a true and fair view of the state of affairs of the Company
at the end of the financial year and of the profit of the
Company for that year;

c) the Directors had taken proper and sufficient care for
the maintenance of adequate accounting records in
accordance with the provisions of the Act for safeguarding
the assets of the Company and for preventing and
detecting fraud and other irregularities;

d) the Directors had prepared the annual accounts on a going
concern basis; and

e) the Directors had devised proper systems to ensure
compliance with the provisions of all applicable laws
and that such systems were adequate and operating
effectively.

COMPLIANCE WITH SECRETARIAL STANDARDS
OF THE INSTITUTE OF COMPANY SECRETARIES OF
INDIA("ICSI")

The Company has complied with the applicable Secretarial
Standards issued by ICSI.

GENERAL DISCLOSURES

The Directors state that no disclosure or reporting is required
in respect of the following items as there were no transactions/
events of these nature during the year under review:

• Issue of equity shares with differential rights as to
dividend, voting or otherwise.

• Issue of Shares (Including Sweat Equity Shares) to
employees of the Company under any scheme

• Significant or material orders passed by the Regulators
or Courts or Tribunals which impact the going concern
status and the Company''s operation in future.

• Voting rights which are not directly exercised by the
employees in respect of shares for the subscription/
purchase of which loan was given by the Company (as
there is no scheme pursuant to which such persons can
beneficially hold shares as envisaged under section 67(3)
(c) of the Companies Act, 2013).

• Revision of financial statements and Directors'' Report of
the Company.

• None of the Directors of the Company has been debarred
or disqualified from being appointed or continuing as a
Director by SEBI/ Ministry of Corporate Affairs/Statutory
Authorities.

• Neither the Managing Director nor the Whole-time
Directors of the Company, receives any commission from
any of its subsidiaries.

GREEN INITIATIVE

Your Company has taken the initiative of going green and
minimising the impact on the environment. The Company has
been circulating the copy of the Annual Report in electronic
format to all those Members whose email address is available
with Company. Your Company would encourage other
Members also to register themselves for receiving Annual
Report in the electronic Report form.

ACKNOWLEDGEMENT

Your directors take this opportunity to thank the Customers, Shareholders, Investors, Suppliers/vendors, Bankers, various
Ministries, Government authorities, business partners/associates and consultants/advisors for their continued support,
encouragement and co-operation extended to the Company. Your Director''s also wish to place on record their deep appreciation
for the commitment and dedication of the employees at all levels that have contributed to the growth of the Company.

For and on Behalf of the Board of Directors of
Mahamaya Lifesciences Limited

Krishnamurthy Ganesan Prashant Krishnamurthy

Managing Director Director

DIN: 00270539 DIN: 02179512

Place: Gurugram
Date: August 25, 2026

Mar 31, 2025

Your Directors are pleased to share with you the 23rd Directors'' Report of your Company
along with the Audited Standalone and Consolidated Financial Statements for the financial
year ended March 31, 2025 ("Year under review").

FINANCIAL SUMMARY AND HIGHLIGHTS

Key highlights of financial performance of your Company for the Financial Year 2024-25 are
given below:

Amount (Rs. In Lacs)

Particulars

Standalone

Consolidated

31.03.2025

31.03.2024

31.03.2025

31.03.2024

Revenue from Operations

26,414.86

16,157.09

26,414.86

16,157.09

Other Income

302.44

124.88

302.44

124.88

Total Income

26,717.31

16,281.97

26,717.31

16,281.97

Total Expenses

24,979.77

15,529.75

24,980.97

15,539.16

Profit before tax

1,726.41

752.22

1,725.20

742.81

Total tax expenses

444.35

205.21

444.04

205.21

Profit for the year

1282.06

547.01

1281.16

537.60

EPS (post bonus)

7.55

3.98

7.55

3.91

During the year under review, Standalone revenue is Rs. 26,414.86 lacs as compared to Rs.
16,157.09 lacs in the prior year. Profit before Tax reported to Rs. 1,726.41 lacs as compared
to profit of Rs. 752.22 lacs in the prior year. Standalone EBITDA for the year under review
increased by 76.31% from Rs. 2586.69 lacs in the prior year to Rs. 1467.12 lacs primarily
due to increase in sales. The Company''s Standalone Profit for the year ended 31st March 2025
is Rs. 1282.06 lacs as against Standalone Profit of Rs. 547.01 lacs for the prior financial year.

Consolidated revenue has also increased from Rs. 16,157.09 lacs to Rs. 26,414.86 Lacs. Your
Company has posted Consolidated profit before Tax of Rs. 1725.20 lacs in the current
financial year as against Consolidated profit before Tax of Rs. 742.81 lacs in the prior
financial year. The Company''s Consolidated profit for the year ended 31st March 2025 is Rs.
1281.16 lacs as against Consolidated Profit of Rs. 537.60 lacs in the prior financial year.

PERFORMANCE OF COMPANY AND FUTURE OUTLOOK

The Company has recorded strong growth in demand for its flagship products, Glufosinate
Ammonium 13.5% SL
and Emamectin 5% SG, driven by their superior quality and
consistent performance. In addition to the continued trust of its existing customer base,
several reputed clients such as
Atul Limited, IFFCO-MC, and DCM Shriram, have
commenced buying products from the Company, further strengthening its market position.

In line with its strategy of innovation and value creation, the Company has initiated Research
& Development activities
focused on developing new formulations and enhancing process
efficiency for the synthesis of active ingredients. These initiatives are expected to enhance
operational efficiency, broaden the product portfolio, and strengthen long-term
competitiveness.

Additionally, the Company is actively pursuing export opportunities and working towards
obtaining more product registrations in new international markets, with a special focus on the
Middle East and Africa.

CONSOLIDATED FINANCIAL STATEMENTS

In accordance with the provisions of the Act, the audited Consolidated Financial Statements
forms part of the Annual Report. The highlights of consolidated financial statements are
included in tables above.

TRANSFER TO RESERVE

Considering the financial position, no amount was transferred to the General Reserves for the
year under review.

DIVIDEND

Considering the financial position of your company, your directors are constrained not to
recommend any dividend for FY 2024-25.

STATE OF COMPANY''S AFFAIRS

During the year under review, the Company was converted from a Private Limited Company
into a Public Limited Company. Consequently, the Company received a fresh Certificate of
Incorporation bearing CIN: U24233DL2002PLC115261, reflecting the change of name to
Mahamaya Lifesciences Limited, from the Registrar of Companies, Delhi, on November 19,
2024.

Further, the Company filed its Draft Red Herring Prospectus (DRHP) with the Bombay Stock
Exchange (BSE) in connection with the proposed listing of its Equity Shares and is pleased to
inform that it has received the in-principle approval from BSE on August 7, 2025.

SUBSIDIARY AND ASSOCIATE COMPANIES

As on 31st March 2025, the Company has one subsidiary:

Name of Subsidiary Group

Country of Incorporation

Percentage Holding As
at March 31, 2025

Mahamaya Lifesciences FZE

United Arab Emirates

100%

Total capital contribution to be made in Mahamaya Lifesciences FZE, is AED 150,000/- out
of which, the Company has remitted AED 10,000 in 2018 & AED 15,000 in 2019 and is
planning to remit the balance in FY 25-26 and complete the investment.

A statement containing the salient features of the financial statement of our subsidiaries in
the prescribed Form AOC-1 is attached herewith as “
Annexure-A”

Further, the Company does not have Joint Venture or Associate Company.

SHARE CAPITAL

Authorised Share Capital

As on March 31, 2025, the authorized share capital of the Company stood at Rs.
25,00,00,000/- (Rupees Twenty-Five Crores Only) divided into 2,50,00,000 (Two Crore Fifty
Lacs only) Equity Shares of Rs. 10/- (Rupee Ten only).

During the year under review, the authorized share capital of the Company increased from
Rs. 2,00,00,000 (Rupees Two Crores only) to Rs. 25,00,00,000/- (Rupees Twenty-Five Crores
only) on 20th July 2024.

Paid up Share Capital

As on March 31, 2025, the Paid-up Share Capital of the Company stood at Rs. 17,76,62,000/-
(Rupees Seventeen Crores Seventy-Six Lacs Sixty-two Thousand only) divided into
1,77,66,200 (One Crore Seventy-seven Lacs Sixty-six Thousand and Two Hundred only)
Equity Shares of Rs. 10/- (Rupee Ten only).

During the year under review, the following changes occurred in the Paid-up Share Capital of
the Company:

1. the Company has issued 2,19,450 equity shares of Rs. 10/- (Rupees Ten only) on 17th
July 2024 on right issue basis, and

2. the Company has issued 1,46,82,000 bonus shares of Rs. 10/- (Rupees Ten only) on
24th July 2024 to the existing shareholder, and

3. the company has issued 16,16,000 equity shares of Rs. 10/- (Rupees Ten only) each at
a premium of Rs. 74/- (Rupees Seventy-Four only) by way of private placement on
11th September 2024.

ALTERATION OF MEMORANDUM OF ASSOCIATION

During the year under review, your Company has altered its Memorandum of Association
(“MOA”) twice. Firstly, to bring in the amendments related to Capital Clause with effect
from 20th July 2024, secondly, the entire set of MOA was replaced with new set of MOA in
line with Companies Act, 2013 pursuant to shareholders’ approval for conversion of Private
Limited Company to Public Limited Company with effect from 29th October 2024.

ALTERATION OF ARTICLES OF ASSOCIATION

During the year under review, your Company had altered its Articles of Association (AOA)
and the entire set of AOA was replaced with new set of AOA in line with Companies Act,
2013 pursuant to shareholders’ approval for conversion of Private Limited Company to
Public Limited Company with effect from 29th October 2024.

REGISTERED OFFICE OF COMPANY

During the year under review, there is no change in the registered office of your company
CHANGE IN NATURE OF BUSINESS

There has been no change in the nature of business of the Company.

ADHERENCE TO SECRETARIAL STANDARDS ISSUED BY INSTITUTE OF
COMPANY SECRETARIES OF INDIA

Your director’s state that applicable Secretarial Standards, i.e. Secretarial Standard-1 on
Meetings of the Board of Directors and Secretarial Standard-2 on General Meetings of
Shareholders issued by the Institute of Company Secretaries of India have been duly followed
by the Company.

BORAD OF DIRECTORS

The composition of the Board is in the compliance with the applicable provisions of the
Companies Act, 2013 and the rules framed thereunder and other applicable laws.

As on March 31, 2025, the Board of Directors of the Company comprised of 6 Directors, as
detailed below:

S. No.

Name

DIN

Designation

1

Mr. Krishnamurthy Ganesan

00270539

Managing Director

2

Mrs. Lalitha Krishnamurthy

00425675

Whole-time Director

3

Mr. Prashant Krishnamurthy

02179512

Director

4

Dr. Charudatta Digambar Mayee

03607287

Independent Director

5

Mr. Sekhar Kavasseri Rajagopalan

03168413

Independent Director

6

Dr. Gopal Krishna Raju

00860886

Independent Director

CHANGES IN DIRECTORSHIPS DURING THE YEAR UNDER REVIEW

During the year under review, the following changes have taken place in the composition of
the Board of Directors of the Company:

a) Mrs. Lalitha Krishnamurthy (DIN: 00425675) was re-designated as the Whole-time
Director of the Company w.e.f. 7th June 2024.

b) Mr. Prashant Krishnamurthy (DIN: 02179512) was re-designated as Executive Director of
the Company w.e.f. 7th June 2024.

c) Dr. Charudatta Digambar Mayee (DIN: 03607287), Mr. Sekhar Kavasseri Rajagopalan
(DIN: 03168413) and Dr. Gopal Krishna Raju (DIN: 00860886) were appointed as Additional
Director (Independent Director) of the Company w.e.f. 11th December 2024. Later, in the
Extra-ordinary General Meeting held on 27th December 2024, the members of the Company
have ratified their appointment as the Independent Directors.

Except as stated above, there was no change in the Directors of the Company during the year
under review.

DIRECTORS LIABLE TO RETIRE BY ROTATION

In terms of Articles of Association of the Company and provisions of the Act,

a) Mr. Prashant Krishnamurthy (DIN: 02179512) is liable to retire by rotation at the ensuing
AGM and being eligible, offered himself for re-appointment.

The Board of Directors recommend his re-appointment for consideration by the shareholders
of the Company at the ensuing AGM.

CHANGES IN DIRECTORSHIPS POST CLOSURE OF THE YEAR UNDER
REVIEW

There is no change in the composition of the Board of Directors of the Company after the
closure of the Financial Year 2024-25.

OTHER KEY MANAGERIAL PERSONNEL

During the year under review, following changes have taken place amongst Other Key
Managerial Personnel:

a) Mr. Prashant Krishnamurthy (PAN: ASFPK0640M) was appointed as the Chief Financial
Officer of the Company w.e.f. 7th June 2024.

b) Ms. Shilpi Bhardwaj was appointed as the Company Secretary and Compliance officer of
the Company w.e.f. 11th November 2024.

Further, except as stated above, there was no change in the Key Managerial Personnel of the
Company during the year under review.

DECLARATION OF INDEPENDENT DIRECTORS

The Independent Directors have submitted their declaration under Section 149 and 150 of the
Act read with rules made thereunder with respect to their Independence and the confirmation
of compliance with the code of conduct for Independent Directors prescribed in Schedule IV
of the Companies Act, 2013 and rules made thereunder.

Further, they have confirmed that they have obtained registration with Indian Institute of
Corporate Affairs as an Independent Director, and such registration continues to be valid.

Based on the declarations and confirmations received from the Independent Directors, the
Board is of the opinion that none of the Independent Directors of the Company are
disqualified from being appointed as Independent Directors of the Company.

Further, in terms of Rule 8(5) of the Companies (Accounts) Rule, 2014, the Board is of the
opinion that all Independent Directors of the Company possess requisite integrity, expertise,
experience and proficiency.

MATERIAL CHANGES AND COMMITMENT IF ANY AFFECTING THE
FINANCIAL POSITION OF THE COMPANY OCCURED BETWEEN THE END OF
THE FINANCIAL YEAR TO WHICH THIS FINANCIAL STATEMENTS RELATE
AND THE DATE OF THE REPORT

Except as mentioned above, no other material changes took place affecting the financial
position of the Company occurred between the end of the financial year to which this
financial statement relate and the date of the report.

AUDITORS AND AUDITORS’ REPORT

Statutory Auditors

M/s. N Naresh & Co., Chartered Accountants were appointed as the Statutory Auditors of the
Company on 29th October 2024, to fill the casual vacancy caused due to resignation of M/s
CHANDRAMOULI AND ASSOCIATES LLP (firm Registration No. 014844S/ S000068),
Chartered Accountants on 7th October 2024, for the financial year 2024-25, till the conclusion
of ensuing Annual General Meeting of the Company to be held in a year 2025.

M/s N Naresh & Co., Chartered Accountants (Firm Registration No.: 0011293S) are proposed
to be re-appointed as Statutory Auditors for the period of 5 years till the conclusion of the 28th
Annual General Meeting of the Company will be held in the year 2030.

Auditors’ report

The Auditors'' Report read together with Annexures referred to in the Auditors'' Report for the
financial year ended March 31, 2025 does not contain any qualification, reservation, adverse
remark or disclaimer.

During the year under review, the Statutory Auditor has not reported any matter of fraud
under Section 143 (12) of the Act, therefore no disclosure is required under Section 134(3)
Companies Act.

The Notes to Accounts referred to in the Auditors'' Report are self-explanatory.

Internal Auditors

Your Company has, pursuant to the provisions of Section 138 of the Companies Act 2013 and
rules made thereunder, appointed M/s CHANDRAMOULI AND ASSOCIATES LLP,
Chartered Accounts, as the Internal Auditors for Financial Year 2024-25 in the Board meeting
held on 10th October 2024.

Secretarial Auditors & their Report

The provisions related to appointment of Secretarial Auditors as per the provisions of Section
204 of the Companies Act 2013 are not applicable on your company for FY 2024-25.

Maintenance of Cost Records

Your Company is required to maintain cost records as specified under Section 148(1) of the
Companies Act, 2013, and accordingly, such accounts and records are made and maintained
in the prescribed manner.

As per provision of the Companies Act, on recommendation of the Audit committee, your
directors have appointed M/s. Yogesh Gupta & Associates, Cost Accountants (having Firm’s
Registration No. 00373) to conduct the audit of the Cost Accounts of the Company.

A Resolution seeking ratification of remuneration payable to M/s. Yogesh Gupta &
Associates, Cost Accountants, for the Financial Year 2025-26 is included in the Notice
convening the Annual General Meeting.

INTERNAL FINANCIAL CONTROL AND ITS ADEQUACY

The Board has adopted the policies and procedures for ensuring the orderly and efficient
conduct of its business, including adherence to the Company''s policies, systems, protocols
and plan implementation for safeguarding of its assets, the prevention and detection of frauds
and errors, the accuracy and completeness of the accounting records, and the timely
preparation of reliable financial disclosures.

IMPLEMENTATION OF RISK MANAGEMENT POLICY OF THE COMPANY

The company has in place a mechanism to identify, assess, monitor, and mitigate various
risks to key business objectives. Major risk identified by the business and functions are
systematically addressed through mitigating actions on continuous basis. The company does
not have any Risk Management Policy as the elements of risk threatening the Company’s
Existence are very minimal.

DETAILS OF POLICY DEVELOPED AND IMPLEMENTED BY THE COMPANY
ON ITS CORPORATE SOCIAL RESPONSIBILTY INITITATIVES

Your Company has developed and implemented the Corporate Social Responsibility Policy in
line with Section 135 of the Companies Act, 2013 read with rules made thereunder and
Schedule VII of the Companies Act, 2013.

As per the policy, following are the focus areas:

1. Promotion of Education and Vocational Skills

2. Social Welfare

3. Empowerment of Women

4. Sanitation and Health Care

5. Conservation of Environment

6. Rural Development Projects

7. Disaster Relief

8. Conservation of National Heritage, Art, Culture and other related activities

Annual Report on the CSR initiatives undertaken by the Company is enclosed herewith as
Annexure-B.

The CSR policy is uploaded on the website of the Company
www. mahamay alifes ciences.com.

DEPOSITS

S. No.

Particulars

Amount

1

Accepted during the year

NIL

2

Remained unpaid or unclaimed as at the end of the year

NIL

3

Default in repayment of deposits or payment of Interest
thereon during the year and if so, number of such cases and
total amount involved:

a. At the beginning of the year

NIL

b. Maximum during the year

NIL

c. At the end of the year

NIL

Since the company did not accept any deposits, therefore Rule 5(vi) of rule 8 of Companies
(Accounts) Rules, does not apply.

PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS MADE UNDER
SECTION 186 OF THE COMPANIES ACT, 2013

Particulars of guarantee and investments made are given in Notes to the Standalone Financial
Statements, respectively, forming an integral part of the Integrated Annual Report. During
Financial Year 2024-25, the Company has not given any loan pursuant to Section 186 of the
Act.

TRANSFER OF UNCLAIMED/UNPAID AMOUNTS TO THE INVESTOR
EDUCATION AND PROTECTION FUND (IEPF)

During the period under review, your Company has not transferred any unclaimed/unpaid
amount to the Investor Education and Protection Fund (IEPF).

EXTRACT OF ANNUAL RETURN

The Annual Return of the Company as on March 31, 2025 is available on the Company''s
website and can be accessed at
www.mahamayalifesciences.com.

During the financial year 2024-25, the Board of Directors of the Company met 14 times and
were duly attended by the Directors. The interval between any two meetings did not exceed
120 days as per the provisions of Companies Act, 2013.

(Q1) April -
June

(Q2) July -
September

(Q3) October -
December

(Q4) January -
March

02-April -24

17-Jul-24

10-Oct-24

06-Jan-25

07-June-24

24-Jul-24

15-Nov-24

09-Jan-25

19-June-24

16-Aug-24

11 -Dec-24

18-Feb-25

-

11-Sep-24

-

25-Feb-25

S. No

Name of the Director

Attendance

1

Mr. Krishnamurthy Ganesan

14/14

2

Mrs. Lalitha Krishnamurthy

14/14

3

Mr. Prashant Krishnamurthy

14/14

4

Dr. Charudatta Digambar Mayee

04/04

5

Mr. Sekhar Kavasseri Rajagopalan

04/04

6

Dr. Gopal Krishna Raju

04/04

COMMITTEES OF THE BOARD

During the period under review, your Company had the following committees:

Audit Committee

The Board of Directors of your Company has duly constituted Audit Committee in
accordance with Section 177 of the Act. During the year under review, all the
recommendations made by the Audit Committee were accepted by your Board.

The constitution of the Audit Committee is as follows:

S. No

Name of the Member

Designation

Position in
Committee

1

Dr. Gopal Krishna Raju

Director (Independent
& Non-Executive)

Chairman & Member

2

Dr. Charudatta Digambar
Mayee

Director (Independent
& Non-Executive)

Member

3

Mr. Krishnamurthy Ganesan

Managing Director

Member

During the year under review, the company has compiled in conducting the meeting as per
terms of reference of Audit committee.

Nomination and Remuneration Committee

The Board of Directors of your Company has duly constituted Nomination and Remuneration
Committee (NRC) in accordance with Section 178 of the Act.

During the year under review, all the recommendations made by the NRC were accepted by
your Board.

The constitution of the NRC is as follows:

S. No

Name of the Member

Designation

Position in
Committee

1

Dr. Charudatta Digambar
Mayee

Director (Independent
& Non-Executive)

Chairman & Member

2

Dr. Gopal Krishna Raju

Director (Independent
& Non-Executive)

Member

3

Sekhar Kavasseri Rajagopalan

Director (Independent
& Non-Executive

Member

During the year under review, the company has compiled in conducting the meeting as per
terms of reference of Nomination and Remuneration committee (NRC).

Corporate Social Responsibility Committee

The Board of Directors of your Company has duly constituted Corporate Social
Responsibility (CSR) Committee in terms of the Section 135 of the Act.

The constitution of CSR Committee is as follows:

Position in Committee

S.No Name of the Member Designation

1. Mr. Krishnamurthy Ganesan Managing Director Chairman & Member

2 Mr. Sekhar Kavasseri Director (Independent m b

. Rajagopalan & Non-Executive) em er_

Whole Time Director

3 Mrs. Lalitha Krishnamurthy Member

During the year under review, the company has compiled in conducting the meeting as per
terms of reference of Corporate Social Responsibility committee.

Stakeholders'' Relationship Committee

The Board of Directors of your Company has duly constituted Stakeholder''s Relationship
Committee (SRC) in terms of the Section 178 of the Act.

The constitution of the SRC is as follows:

S. No

Name of the Member

Designation

Position in
Committee

1

Dr. Gopal Krishna Raju

Director (Independent &
Non-Executive)

Chairman & Member

2

Prashant Krishnamurthy

Executive Director & CFO

Member

3

Lalitha Krishnamurthy

Whole Time Director

Member

PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED
PARTIES

During the year, the contract or arrangement entered with related parties as defined under the
provision of 188 (1) of Companies Act, 2013 read with rule 8(2) of Companies (Accounts)
Rules, 2014 was at arm length basis. The details of such transactions in Form AOC-2 are
annexed herewith and marked as
Annexure-C to this Report.

All related party transactions were placed before the Audit Committee and also the Board for
their approval. The Company has framed a policy on RPTs for the purpose of identification,
approval and monitoring of such transactions. The policy on Related Party Transactions is
hosted on the Company’s website at
www.mahamayalifesciences.com.

COMPANY''S POLICY RELATING TO DIRECTORS'' APPOINTMENT, PAYMENT
OF REMUNERATION AND DISCHARGE OF THEIR DUTIES

Your Company has Nomination and Remuneration policy in place relating to the appointment
of Directors, payment of managerial remuneration, Directors'' qualifications, positive
attributes, independence of Directors and other related matters as provided under Section
178(3) of the Act. The aforesaid policy is uploaded on the website of the Company at
www.mahamayalifesciences.com.

The Remuneration Policy of the Company reflects the remuneration philosophy and
principles of the Company and considers the pay and employment conditions with
peers/competitive market to ensure that pay structures are appropriately aligned. Ensure
reasonableness and sufficiency of remuneration to attract, retain and motivate competent
resources.

Ensure a balance between rewarding personnel of the Company in relation to short and long¬
term performance of the Company.

DISCLOSURE OF VIGIL MECHANISM

The concept of vigil mechanism is not applicable to your company.

The Company being an unlisted Public Company and paid up Capital is less than Rs. 25
Crore, therefore provisions of Section 134 (3) (p) of the Companies Act, 2013 relating to
annual evaluation of Board are not applicable to your Company.

INSOLVENCY AND BANKRUPTCY CODE, 2016/ ONE-TIME SETTLEMENT

During the year under review, the Company has nothing to report in terms of Clause (xi) and
(xii) of sub-rule 5 of Rule 8 of the Companies (Accounts) Rules, 2014. During the year under
review, the Company has neither made any application nor any proceedings are pending
under the Insolvency and Bankruptcy Code, 2016. Similarly, the Company has not made any
one-time settlement with banks or financial institutions during the period under review.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN
EXCHANGE EARNINGS AND OUTGO

The particulars as prescribed under the provisions of the Companies Act, 2013 read with
Rules framed there under, are set out herein below:

i CONSERVATION OF ENERGY

Though the Company does not have energy intensive operation, every endeavour has been
made to ensure the optimal usage of energy, avoid wastage and conserve energy. The
Company constantly evaluates new technologies and makes appropriate investments to be
energy efficient.

During the year under review, the Company adopted various energy conservation options /
technologies and took measures to reduce energy consumption by using energy efficient
equipment and devices, replacing existing CFL fittings with LEDs fittings to reduce power
consumption, timely preventive maintenance of all major and minor equipment.

i TECHNOLOGY ABSORPTION

The Company is regularly making efforts towards technology absorption.

. FOREIGN EXCHANGE EARNINGS AND OUTGO

The Particulars regarding total foreign exchange earnings and outgo by the company during
the period under review are as under:

Particulars

Amount in Rs

Earning in foreign currency due to exports of goods/services.

1,347.08

Expenditure in foreign currency

15,405.48

PARTICULARS OF EMPLOYEES

Since the Company is unlisted public Company for the year under review, the provisions of
Section 197(12) of the Companies Act, 2013 read with Rule 5 of the Companies
(Appointment and Remuneration of Managerial Personnel) Rule, 2014 are not applicable to
your Company.

DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE
REGULATORS/COURTS/TRIBUNALS IMPACTING THE GOING CONCERN
STATUS AND THE COMPANY''S OPERATIONS IN FUTURE

There was no such significant and material order passed by the regulators/courts/tribunals
during the financial year under review. However, your Company was converted from Private
Limited Company to Public Limited Company during the financial year under review.

DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT
WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

To foster a positive workplace environment, free from harassment of any nature the
Company has constituted an Internal Complaints Committee (ICC) to consider and address
the sexual harassment complaints in accordance with the Sexual Harassment of Women at
Workplace (Prevention, Prohibition & Redressal) Act, 2013 and has in place an Anti-Sexual
Harassment Policy in line with requirements of the said Act. The following is a summary of
sexual harassment complaints received and disposed-off during the financial year 2024-25:

PARTICULARS

DETAILS

STATUS

No. of complaints filed during the financial year

None

NA

No. of complaints pending as on end of the

None

NA

financial year

MATERNITY BENEFIT PROVIDED BY THE COMPANY UNDER MATERNITY
BENEFIT ACT 1961

The Company declares that it has duly complied with the provisions of the Maternity Benefit
Act, 1961. All eligible women employees have been extended the statutory benefits
prescribed under the Act, including paid maternity leave, continuity of salary and service
during the leave period, and post-maternity support such as nursing breaks and flexible
return-to-work options, as applicable.

The Company remains committed to fostering an inclusive and supportive work environment
that upholds the rights and welfare of its women employees in accordance with applicable
laws.

DIRECTORS’ RESPONSIBILITY STATEMENT

In accordance with the provisions of Section 134(5) of the Companies Act, 2013 the Board
hereby submits its Responsibility Statement for the year under review, that

a) in the preparation of the annual accounts, the applicable accounting standards had
been followed along with proper explanation relating to material departures;

b) the Directors had selected such accounting policies and applied them consistently and
made judgments and estimates that are reasonable and prudent so as to give a true and
fair view of the state of affairs of the Company at the end of the financial year and of
the profit of the Company for that year;

c) the Directors had taken proper and sufficient care for the maintenance of adequate
accounting records in accordance with the provisions of the Act for safeguarding the
assets of the Company and for preventing and detecting fraud and other irregularities;

d) the Directors had prepared the annual accounts on a going concern basis; and

e) the Directors had devised proper systems to ensure compliance with the provisions of
all applicable laws and that such systems were adequate and operating effectively.

ACKNOWLEDGEMENT

Your directors take this opportunity to thank the Customers, Shareholders, Investors,
Suppliers/vendors, Bankers, various Ministries, Government authorities, business
partners/associates and consultants/advisors for their continued support, encouragement and
co-operation extended to the Company. Your Director’s also wish to place on record their
deep appreciation for the commitment and dedication of the employees at all levels that have
contributed to the growth of the Company.

For and on Behalf of the Board of Directors of

Mahamaya Lifesciences Limited

Krishnamurthy Ganesan Prashant Krishnamurthy

Managing Director Director

DIN: 00270539 DIN: 02179512

Place: Gurugram
Date: 29.08.2025

Mar 31, 2024

Your directors have pleasure in presenting the 22nd Director Report on the business operations
of Mahamaya Lifesciences Private Limited
(''''the Company") together with standalone and
consolidate audited financial statement of your company for the financial year ended 31st
March 2024.

1. FINANCIAL HIGHLIGHTS:

(Rs in lakhs)

Particulars

Standalone Financials
Parameters

Consolidated Financial
Parameters

31st March
2024

31st March
2023

31st March
2024

31st March
2023

Total Revenue

16,281.97

13,738.89

16,281.97

13,738.89

Less: Total Expense

15,529.75

13,218.16

15,539.16

13,222.26

Profit Before Tax

752.22

520.73

742.81

516.63

Less: Tax Expenses

205.21

147.89

205.21

147.89

Net Profit After Tax

547.01

372.85

537.60

368.75

2. REVIEW OF BUSINESS OPERATIONS AND STATUS OF COMPANY''S AFFAIRS:

The results of business operations Company''s affairs are summarized below:

Operations: (All figures in Rs. "lakhs")

Standalone-

Your Directors are pleased to inform you that your Company has achieved a growth of 18%
y-o-y with a total revenue of INR 16,161.85 (FY 2022-23 13,719.27) and a PAT of INR 547.01
(FY 2022-23 372.85), which is 47% higher than the last year. This improved performance was
possible due to the Company''s efforts in identifying new products and markets, sustained
efforts to improve the efficiency of operations and increased focus on manufacturing.

The SG Plant and the SL Plant at the formulations plant are running efficiently and your
Directors expect to increase the manufacturing capacity utilization further in the coming FY
2024-25.

Your Company is planning to put up additional machineries in the plant in FY 24-25 by which
the Company will be able to add more products in its repertoire.

Consolidated - For Financial Year ended 31st March 2024, the total revenue from operation of
the Company was INR 16,161.85(FY 2022-23 13,719.27). The PAT for Financial Year ended 31st
March 2024 was INR 537.60 (FY 2022-23 368.75). The Subsidiary has incurred a net loss of INR
9.41 during the year.

Your Company is in the process of registering products in the African Markets which the
Company expects to complete in the next financial year. The Subsidiary at UAE is already in
the process of identifying prospective customers and the Company expects to start supplies to
the African markets by that time.

Your Directors are hopeful and confident that the company will grow through innovation,
progressive processes, and effective management interventions by creating organisation of
tomorrow with the growing business across the countries and thereby supporting in the
overall growth of the Company.

3. CHANGES IN THE NATURE OF THE BUSINESS, IF ANY;

There has been no change in the nature of the business of the Company during the financial
year ended March 31, 2024.

4. DIVIDEND:

The Board has not recommended any dividend for the Financial Year ended 31st March 2024.

5. AMOUNTS TRANSFERRED TO RESERVES:

The Company has posted profits however, for the future growth of the Company, the Board
does not propose to transfer any amount to general reserves of the Company.

6. DEPOSITS:

The Company has not accepted any deposits from the public under Section 73 of the
Companies Act, 2013 read with Companies (Acceptance of Deposits) Rules, 2014 and no
amount on account of principal or interest on public deposits was outstanding as on the
balance sheet date.

7. ISSUED AND PAID UP CAPITAL:

The issued & paid-up share capital of the Company as on 31st March 2024 was INR 124.88 (Rs
in "lakhs") divided into 12,48,750 Equity shares of INR 10/- each.

8. MATERIAL CHANGES AND COMMITMENT AFFECTING THE FINANCIAL
POSITION OF THE COMPANY:

There have been no material changes and commitments affecting the financial position of the
Company occurred between the end of the financial year of the Company to which the
financial statements relate to and the date of this report.

9. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS MADE UNDER
SECTION 186 OF THE COMPANIES ACT, 2013:

During the year, the Company had not given any loan/ guarantee, made any investments or
provided any security to any Body Corporate or Person as covered under section 186 of the
Act.

10. PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED
PARTIES U/S 188 OF THE COMPANIES ACT 2013:

During the year, the contract or arrangement entered with related parties as defined under
the provision of 188 (1) of Companies Act, 2013 read with rule 8(2) of Companies (Accounts)
Rules, 2014 was at arm length basis. The details of such transactions in Form AOC-2 is
annexed herewith and marked as
Annexure-A to this Report.

11. NUMBER OF BOARD MEETINGS:

During the financial year 2023-24, the Board of Directors of the Company met 22 times and
were duly attended by the Directors. The interval between any two meetings did not exceed
120 days as per the provisions of Companies Act, 2013.

(Ql) April -
June

(Q2) July -
September

(Q3) October -
December

(Q4) January -
March

20-Apr-23

10-May-23

19-May-23

31-May-23

27-Jun-23

30-Jun-23

10-Jul-23

18-Jul-23

30-Jul-23

25-Aug-23

29-Aug-23

07-Sep-23

16-Sep-23

29-Sep-23

02-No v-23
06-Nov-23
Ol-Dec-23
27-Dec-23

03-Jan-24
01-Feb-24
12-Feb-24
27-Feb-24

S.No

Name of the Director

Attendance

1

Krishnamurthy Ganesan

22/22

2

Prashant Krishnamurthy

22/22

3

Lalitha Krishnamurthy

22/22

12. DIRECTORS'' & KEY MANAGERIAL PERSONNEL

Mr. Krishnamurthy Ganesan, Mrs. Lalitha Krishnamurthy and Mr. Prashant Krishnamurthy
are the directors of the Company.

Further, no director or key managerial personnel was appointed or have resigned during the
financial year 2023-24.

13. FRAUD REPORTING:

The Board of Directors state that no report is required regarding this clause as there has been
no fraud in the Company during the financial year 2023-24.

14. APPOINTMENT OF AUDITORS

M/s CHANDRAMOULI AND ASSOCIATES LLP, Chartered Accountants, (Firm
Registration No. 014844S/S000068) is continuing as Statutory Auditors of the Company and
they are holding the office till the conclusion of Annual General Meeting for the period
ending March 31, 2025.

15. EXPLANATIONS TO AUDITORS REMARKS:

No qualification, reservation or adverse remarks or disclaimer have been made by the
Auditor''s in their Audit Report. The Auditor''s Report is self-explanatory.

16. QUALIFICATION TO SECRETARIAL AUDITOR REMARKS:

The Secretarial Audit report for the Company is not applicable for the financial year ended
31st March 2024.

17. DETAILS OF SUBSIDIARY, JOINT VENTURE OR ASSOCIATE COMPANY;

As on 31st March 2024, the Company has a subsidiary as given below

Name of Subsidiary Group

Country of Incorporation

Percentage Holding As at
March 31, 2024

Mahamaya Lifesciences FZE

United Arab Emirates

100%

Mahamaya Lifesciences Pvt Ltd

Australia

100%

Total capital contribution to be made in Mahamaya Lifesciences FZE, is AED 150,000/- out of
which, the Company has remitted AED 10,000 in 2018 & AED 15,000 in 2019 and is planning
to send the balance in FY 24-25 and complete the investment.

The Company has incorporated a wholly owned subsidiary, viz., Mahamaya Lifesciences Pty
Ltd in Melbourne, Australia on 15-05-2018. However, capital contribution has not been done
since bank account for the subsidiary is not yet opened and the subsidiary is yet to start the
operations.

A statement containing the salient features of the financial statement of our subsidiaries in
the prescribed Form AOC-1 is attached herewith as
"Annexure-B".

Further, the Company does not have Joint Venture or Associate Company.

18. RISK MANAGEMENT POLICY:

The company has in place a mechanism to identify, assess, monitor, and mitigate various
risks to key business objectives. Major risk identified by the business and functions are
systematically addressed through mitigating actions on continuous basis. The company does
not have any Risk Management Policy as the elements of risk threatening the Company''s
Existence are very minimal.

19. DISCLOSURES UNDER SEXUAL HARASSMENT OF WOMEN AT WORKPLACE
(PREVENTION, PROHIBITION & REDRESSAL) ACT, 2013:

To foster a positive workplace environment, free from harassment of any nature the
Company has constituted an Internal Complaints Committee (ICC) to consider and address
the sexual harassment complaints in accordance with the Sexual Harassment of Women at
Workplace (Prevention, Prohibition & Redressal) Act, 2013 and has in place an Anti-Sexual
Harassment Policy in line with requirements of the said Act.

PARTICULARS

DETAILS

STATUS

No. of complaints filed during the financial

None

NA

year

No. of complaints pending as on end of the

None

NA

financial year

20. MAINTENANCE OF COST RECORDS AS SPECIFIED BY THE CENTRAL
GOVERNMENT UNDER SUB-SECTION (1) OF SECTION 148 OF THE COMPANIES
ACT, 2013

The Company is not required to maintain the Cost Records as Section 148 of the Companies
Act, 2013 is not applicable for the Company for the FY 2023-24. However, since the
Manufacturing turnover of the Company has exceeded INR 30 crores in FY 2023-24, the
maintenance of Cost Accounting Records has become applicable from FY 2024-25.

21. CORPORATE SOCIAL RESPONSIBILITY

The Company is required to spend 2% of the average net profits of the preceding three
financial years u/s 135 of the Companies Act, 2013. However, the Company was not able to
spend the specified amount within the end of the financial year due to other commitments.
Section 135 provides that the unspent amount be donated to a Fund specified in Schedule VII
within a period of six months from the expiry of the financial year. The Board is reviewing its
options and the specified amount will be deposited in accordance with Section 135. Further
details has been attached herewith as
"Annexure-C".

22. SECRETARIAL AUDITORS

In terms of Section 204 of the Companies Act, 2013, the Company is not required to obtain
''Secretarial Audit Report'' from independent practicing company secretary.

23. SECRETARIAL STANDARDS

Your Directors confirm compliance of all applicable Secretarial Standards during the financial
year 2023-24.

24. PARTICULARS OF EMPLOYEES:

During the financial year ended 31st March 2024 under review, the details of
employee/director''s in the Company whose remuneration is falling under the provisions of
Section 197 of Companies Act, 2013 read with Rule 5(2) of The Companies (Appointment and
Remuneration of Managerial Personnel) Rules, 2014 are summarized below

Sr. No.

Name

Amount

1.

N.A.

N.A.

25. CONSERVATION OF ENERGY, RESEARCH AND DEVELOPMENT, TECHNOLOGY
ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:

4. CONSERVATION OF ENERGY

Though the Company does not have energy intensive operation, every endeavour has been
made to ensure the optimal usage of energy, avoid wastage and conserve energy. The
Company constantly evaluates new technologies and makes appropriate investments to be
energy efficient.

During the year under review, the Company adopted various energy conservation options /
technologies and took measures to reduce energy consumption by using energy efficient
equipment and devices, replacing existing CFL fittings with LEDs fittings to reduce power
consumption, timely preventive maintenance of all major and minor equipment.

4 TECHNOLOGY ABSORPTION

The Company is regularly making efforts towards technology absorption

± FOREIGN EXCHANGE EARNINGS AND OUTGO

The Particulars regarding total foreign exchange earnings and outgo by the company during
the period under review are as under:

Particulars

Amount in INR

Earning in foreign currency due to exports of goods/services.

350.72

Expenditure in foreign currency

7,888.39

26. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE
REGULATORS, COURTS, TRIBUNALS IMPACTING THE GOING CONCERN STATUS
AND THE COMPANY''S OPERATIONS:

During the year under review, there are no significant and material orders passed by any
regulators or Courts or Tribunals impacting the going concern status and company''s
operations in future.

27. DIRECTORS RESPONSIBILITY STATEMENT

A statement of responsibility of the directors relating to compliance with the financial
accounting and reporting requirements in respect of the financial statements, as specified
under section 134 (5) of the Companies Act, 2013, is as under:

(a) The applicable Accounting Standards have been followed along with proper
explanations relating to material departures while preparing the Company''s Standalone
and Consolidated Financial Statements for the Financial Year ended 31 March, 2024.;

(b) The directors have selected such accounting policies and applied them consistently and
made judgments and estimates that are reasonable and prudent so as to give a true and
fair view of the state of affairs of the Company at the end of the financial year and of the
profit and loss of the Company for that period;

(c) The Directors have taken proper and sufficient care for the maintenance of adequate
accounting records in accordance with the provisions of the Companies Act, 2013 for
safeguarding the assets of the Company and for preventing and detecting fraud and
other irregularities;

(d) The Directors have prepared the Standalone and Consolidated financial statements on a

going concern basis

(e) The Directors have laid down Internal Financial Controls to be followed by the
Company and such Internal Financial Controls are adequately and operating effectively;
and

(f) The directors have devised proper systems to ensure compliance with the provisions of
all applicable laws and that such systems were adequate and operating effectively.

28. DETAILS IN RESPECT OF ADEQUACY OF INTERNAL FINANCIALS CONTROLS:

The Company has in place adequate internal financial control with reference to the financial
statements. During the year, such controls were tested and no reportable material weakness
in the design or operation was observed.

29. INDEPENDENT DIRECTORS:

Since the Company is not required to appoint independent Directors the requirements of
submitting their disclosures to the Board u/s.149 (6) of the Companies Act, 2013 does not
arise. Since Independent Director''s clause is not applicable there, statement pursuant to Rule
5(iii)(a) of Rule 8 of the Companies (Accounts) Rules, 2014 is not applicable.

30. REMUNERATION POLICY:

The provisions of Section 178(1) relating to constitution of Nomination and Remuneration
Committee are not applicable to the Company and hence the Company has not devised any
policy relating to appointment of Directors, payment of Managerial remuneration, Directors
qualifications, positive attributes, independence of Directors and other related matters as
provided under Section 178(3) of the Companies Act, 2013.

31. INFORMATION AS PER CLAUSES (XI) AND (XII) OF RULE 8(5) OF THE COMPANIES
(ACCOUNTS) RULES, 2014:

There was no application made or any proceeding pending under the Insolvency and
Bankruptcy Code, 2016 in respect of the Company during the financial year ended March 31,
2024 and there was no such application made or any proceeding as at March 31, 2024.

The Company has not entered into any one-time settlement with its lenders during the
financial year ended March 31, 2024 and therefore the requirements of clause (xii) of Rule 8(5)
of the Companies (Accounts) Rules, 2014 are not applicable.

32. ACKNOWLEDGEMENTS:

Your Directors wish to place on record their appreciation to the Employees of the Company
for the contributions made by them and thank the customers, vendors and other business
associates for their continued support. The Directors also wish to thank the Government
Authorities, Bankers, Auditors and the shareholders for their cooperation and assistance that
they have extended towards effective operations of the Company.

By order of the Board

For Mahamaya Lifesciences Private Limited

.

(Krishnamurthy Ganesan) (Prashant Krishnamurthy)

Managing Director Director

DIN: 00270539 DIN: 02179512

Address: ML-25, Eldeco Mansionz, Sohna Address: ML-25, Eldeco Mansionz, Sohna
Road, Sector 48, Gurgaon, Haryana - Road, Sector 48, Gurgaon, Haryana - 122018

122018

Place: New Delhi
Date: 7th June 2024

Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article

Notifications
Settings
Clear Notifications
Notifications
Use the toggle to switch on notifications
  • Block for 8 hours
  • Block for 12 hours
  • Block for 24 hours
  • Don't block
Gender
Select your Gender
  • Male
  • Female
  • Others
Age
Select your Age Range
  • Under 18
  • 18 to 25
  • 26 to 35
  • 36 to 45
  • 45 to 55
  • 55+